Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
No Thumbnail Available
Identifiers
Date
2021-09-21
Authors
Grande, E.
Garcia-Carbonero, R.
Teule, A.
Benavent Vinuales, M.
Jimenez-Fonseca, P.
Molina-Cerrillo, J.
Lopez, C.
Custodio, A.
Hierro, C.
Gallego, J.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
Abstract
Antiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are discouraging. The aim of this trial is to assess the efficacy and safety of the combination of cabozantinib and atezolizumab, which may overcome the resistance in previously treated metastatic endocrine tumors .
Description
MeSH Terms
atezolizumab
Angiogenesis Inhibitors
Immune Checkpoint Inhibitors
Angiogenesis Inhibitors
Immune Checkpoint Inhibitors
DeCS Terms
Neoplasms
Efficacy
Angiogenesis Inhibitors
Safety
Efficacy
Angiogenesis Inhibitors
Safety
CIE Terms
Keywords
cabozantinib, Endocrine Gland Neoplasms
Citation
Grande, E., Garcia-Carbonero, R.. Teule, A., Benavent Vinuales, M., Jimenez-Fonseca, P. , Molina-Cerrillo, J., et al . Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. Septiembre 2021 (32), S624 - S625